Home » Newsletters » BioWorld Science

BioWorld Science

March 15, 1999

View Archived Issues

New treatment strategy successful in patients with severe CHF

Cancer therapeutics joint venture IBC Pharmaceuticals receives start-up funding

Toprol-XL effective in heart failure; MERIT-HF trial results presented

Long-term treatment with phen-fen associated with valvular abnormalities

Eptifibatide lowers MI incidence, heart muscle injury in ACS patients

Telomeres and telomerase linked to cancer, age-related changes

Pliva and Althexis collaborate on structure-based design of new antibiotics

New DAG analogues acting as PKC agonists or antagonists

Zeria patents new series for BPH

New patent issues covering Cytoclonal's novel methods of producing paclitaxel

Orally active analgesic agents in development at Otsuka

N-type calcium channel inhibitors described by Ono

GABA-A receptor ligands from MS&D for Alzheimer's disease

Volunteer study suggests that CMI-977 may be superior to zileuton in both efficacy and safety

New market introduction for Seretide

Kanebo's Na+/H+ exchange inhibitor is a promising treatment for acute coronary syndrome

Venous responsiveness to NE is enhanced in the presence of aspirin

BTG licenses anti-CD3 antibody to LeukoSite

Health Canada approves Rebetron for chronic HCV

FDA grants priority review status, sets date for advisory committee review of Actos

Spanish market introduction announced for antirejection MAb

SkyePharma completes DepoTech acquisition

Hollis-Eden to initiate HIV/AIDS trials with HE-2000 in South Africa

Improvement in seasonal allergic rhinitis following preventive treatment with rhuMAb-E25

Effexor XR receives FDA approval for treatment of GAD

CysLT1 antagonists show potential as Rx for chronic urticaria

Hemosol to begin multinational phase III trials of Hemolink

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...